Proteomics leaders join forces

Proteomics Innovation Network seeks collaborative solutions to unmet needs in drug discovery, personalized medicine
Register for free to listen to this article
Listen with Speechify
0:00
1:00
GARDNER, Mass.—New England Peptide (NEP) recently announced that it has joined with other global leaders in the proteomics field to create the Proteomics Innovation Network, an association of proteomics product and service providers designed to generate collaborative "sample to discovery" solutions across the proteomics spectrum.

"Since proteomics is growing and evolving at such a rapid pace, it is critical for leaders in the field to come together to address the greatest challenges and opportunities in proteomics," explains NEP CEO Dave Robinson. "We are optimistic that this collaboration will fast-track breakthroughs in drug discovery, personalized medicine and more."

Each of the 13 network members has complementary expertise, core technologies and infrastructure to address critical unmet needs in biomarker and drug target discovery, personalized medicine, drug profiling and selective reaction monitoring.  In addition to NEP, the network includes: Australian Proteome Analysis Facility, Covaris Inc., Dualsystems Biotech, Eprogen, Focus Proteomics, Horluce BioConsulting, Innova Proteomics, Neolomed Biosciences LLC, New Liberty Proteomics, Norton Scientific and the Ontario Cancer Biomarker Network.

Founded in 1998, NEP designs and produces custom peptides and polyclonal antibodies for drug and vaccine discovery organizations worldwide. The company's chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications.

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up illustration of clustered, irregularly shaped 3D cell structures resembling organoids, displayed in a blue-toned background.
Machine learning-powered image analysis makes it possible to automatically and reliably quantify complex 3D cell structures.
Illustration of a glowing human brain with interconnected neural networks and bright data points, set against a dark, digital background.
Take a closer look at modern techniques that reveal when, where, and how neurons communicate in real time.
Gloved hand holding a petri dish containing red liquid culture medium against a light blue background.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue